Synthetic Biologics announced an investigator-sponsored Phase 2b study evaluating SYN-010 in patients with irritable bowel syndrome with constipation (IBS-C) will be discontinued. The decision was made following review of data from a planned interim futility analysis, which concluded that although SYN-010 was well-tolerated, it is unlikely the trial will reach its primary objective by the time enrollment is completed. As a result, Cedars-Sinai Medical Center (CSMS) has agreed to discontinue the trial and will conduct a comprehensive review of the final data set and publish its findings.
The Phase 2b study was being conducted by the Medically Associated Science and Technology (MAST) Program at CSMC and was designed to evaluate two dose strengths of oral SYN-010 (21 mg and 42 mg) in patients diagnosed with IBS-C. The primary objective of the study was intended to determine the efficacy of SYN-010, measured as an improvement from baseline in the weekly average number of complete spontaneous bowel movements during the 12-week treatment period for SYN-010 21 mg and 42 mg daily doses relative to placebo.
About Irritable Bowel Syndrome
IBS affects an estimated 10 to 15 percent of the population, or as many as 45 million people in North America. The condition affects both men and women; however, two-thirds of diagnosed sufferers are women. It has been reported that up to 20 percent of all IBS patients have IBS-C and current FDA-approved therapies for the treatment of IBS-C, which include prescription and over-the-counter laxatives, do little to treat the underlying cause of the disease. These products provide patients with temporary relief from the symptoms of constipation by elevating the amount of water which passes through the gastrointestinal tract, but they tend to cause an IBS-C patient to swing from suffering from constipation, to suffering from diarrhea.
SYN-010 is a proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome to treat an underlying cause of IBS-C. SYN-010 is intended to act primarily in the intestinal lumen while avoiding systemic absorption, thereby targeting a major cause of IBS-C, not just the symptoms.
The patent rights covering the use of SYN-010 are owned by Cedars-Sinai Medical Center and are exclusively licensed by Cedars-Sinai Medical Center to Synthetic Biologics.